专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090011440A1 Receptor Tyrosine Kinase Signaling Pathway Analysis For Diagnosis And Therapy 审中-公开
标题翻译：受体酪氨酸激酶信号通路分析诊断和治疗
公开(公告)号：US20090011440A1
公开(公告)日：2009-01-08
申请号：US12176982
申请日：2008-07-21
申请人： Ali Mukherjee , Mengxiang Tang , Harprit S. Pannu , Po-Ying Chan-Hui , Sharat Singh
发明人： Ali Mukherjee , Mengxiang Tang , Harprit S. Pannu , Po-Ying Chan-Hui , Sharat Singh
IPC分类号： G01N33/574 , G01N33/53 , C12Q1/48
CPC分类号： G01N33/74 , G01N33/5041 , G01N33/57492 , G01N33/6893 , G01N2333/485
摘要： The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.
摘要翻译：本发明提供了通过测量受体二聚化和RTK途径特征的蛋白质 - 蛋白复合物或活化的效应蛋白的相对量来确定细胞样品或患者样品中受体酪氨酸激酶（RTK）途径的激活状态的方法。本发明还提供了使用这种状态信息来选择对途径特异性药物有反应的患者的方法，更具体地，涉及用于测量ErbB受体和受体复合物的方法，并使用这些信息来选择对ErbB途径特异性药物有反应的患者。优选地，本发明的方法通过使用具有可释放分子标签的结合化合物组来实现，所述可释放分子标签对于在RTK活化中形成的一种或多种复合物的多种组分是特异性的。结合后，分离标签被释放并与测定混合物分离，用于分析。

2. 发明授权

US07402399B2 Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy 有权
标题翻译：受体酪氨酸激酶信号通路分析诊断和治疗
公开(公告)号：US07402399B2
公开(公告)日：2008-07-22
申请号：US10963855
申请日：2004-10-13
申请人： Ali Mukherjeei , Mengxiang Tang , Harprit S. Pannu , Po-Ying Chan-Hui , Sharat Singh
发明人： Ali Mukherjeei , Mengxiang Tang , Harprit S. Pannu , Po-Ying Chan-Hui , Sharat Singh
IPC分类号： G01N33/53 , G01N33/533
CPC分类号： G01N33/74 , G01N33/5041 , G01N33/57492 , G01N33/6893 , G01N2333/485
摘要： The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.
摘要翻译：本发明提供了通过测量受体二聚化和RTK途径特征的蛋白质 - 蛋白复合物或活化的效应蛋白的相对量来确定细胞样品或患者样品中受体酪氨酸激酶（RTK）途径的激活状态的方法。本发明还提供了使用这种状态信息来选择对途径特异性药物有反应的患者的方法，更具体地，涉及用于测量ErbB受体和受体复合物的方法，并使用这些信息来选择对ErbB途径特异性药物有反应的患者。优选地，本发明的方法通过使用具有可释放分子标签的结合化合物组来实现，所述可释放分子标签对于在RTK活化中形成的一种或多种复合物的多种组分是特异性的。结合后，分离标签被释放并与测定混合物分离，用于分析。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式